The Bethesda System for Reporting Thyroid Cytopathology
Definitions, Criteria, and Explanatory Notes
Page
%P
-
Chapter
Introduction to the Third Edition of the Bethesda System for Reporting Thyroid Cytopathology
The updated 2023 third edition of the Bethesda System for Reporting Thyroid Cytopathology reflects the advances in the field of thyroid cytopathology since the publication of the second edition of the atlas in...
-
Book
-
Article
Open AccessAssessing invasiveness of subsolid lung adenocarcinomas with combined attenuation and geometric feature models
The aim of this study was to develop and test multiclass predictive models for assessing the invasiveness of individual lung adenocarcinomas presenting as subsolid nodules on computed tomography (CT). 227 lung...
-
Chapter
Head and Neck: Thyroid
Thyroid nodules are a frequent finding in the general population, with palpable nodules found in 4–7% of adults and subclinical nodules identified in up to 70% of adults, although the vast majority (90–95%) of...
-
Chapter
Molecular Diagnostics in Lung Cytology
Cytology specimens obtained by minimally invasive procedures have become an increasingly important player for both the diagnosis and ancillary molecular testing in the work-up of patients with lung cancer. The...
-
Article
Open AccessSoftware-based risk stratification of pulmonary adenocarcinomas manifesting as pure ground glass nodules on computed tomography
To assess the performance of the “Computer-Aided Nodule Assessment and Risk Yield” (CANARY) software in the differentiation and risk assessment of histological subtypes of lung adenocarcinomas manifesting as p...
-
Chapter
Suspicious for Malignancy
The term “suspicious for malignancy” (SFM) is applied when the cytologic features of a thyroid fine needle aspiration (FNA) are worrisome for papillary thyroid carcinoma, medullary thyroid carcinoma, lymphoma,...
-
Article
Open AccessRB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, relapse typically occurs after an average of 1 year of...
